has function has role immunizes against disease immunizes recipient test in lab animal model cervical cancer Mus musculus Homo sapiens therapeutic vaccine function DNA vaccine role vaccine in clinical trial role cervical cancer vaccine pNGVL4a-CRT/E7(detox) DNA vaccine Jie Zheng 1489079 5011 PMID:26616223 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5011 NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C88289 Oliver He https://github.com/vaccineontology/VO/issues/123 cancer vaccine Gene name: HPV16 E7 Virginia He A cancer vaccine consisting of the DNA plasmid pNGVL4a-A encoding calreticulin (CRT) linked to a detox form of human papillomavirus (HPV) type 16 E7 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, this vaccine may generate a potent cytotoxic T-lymphocyte (CTL) response against E7-expressing tumor cells, resulting in tumor cell death. For E7(detox), the amino acids in E7 at positions 24 (cysteine to glycine) and 26 (glutamic acid to glycine) were substituted. CRT, a 46 kDa protein located in the lumen of the cell's endoplasmic reticulum (ER), may potentiate MHC class I presentation of HPV-16 E7 to E7-specific CD8-positive T cells. In addition, pNGVL4a-A contains two short immunostimulatory DNA sequences (ISS) in the noncoding region, which may elicit the production of IFN- and IL-12 in transfected keratinocytes and dermal antigen presenting cells (APCs), resulting in a potent T helper cell type 1 response. NCT: https://clinicaltrials.gov/ct2/show/NCT00988559 Jimmy Guo therapeutic cancer vaccine DNA cancer vaccine